查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1239516

肌张力障碍治疗市场：按药物类型、给药途径和分销渠道分类：2021-2031 年全球机遇分析和行业预测

Dystonia Drugs Market By Drug Type, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 210 Pages | 商品交期: 2-3个工作天内

价格

2021 年全球肌张力障碍治疗市场价值 8.0667 亿美元，从 2022-2031 年以 5.5% 的复合年增长率增长到 2031 年的 13.7867 亿美元，预计将达到美元。

肌张力障碍有时被定义为一种运动障碍，其特征是肌肉不自主收缩，导致重复和扭曲运动。 该病症可能影响身体的一个部位（局灶性肌张力障碍）、两个部位（节段性肌张力障碍）或全身，称为全身性肌张力障碍。 这些肌肉收缩从轻微到严重不等，并且会因姿势异常而影响人的运动。 也有人说，女性比男性更容易患上这种疾病。 肌张力障碍的症状包括腿部抽筋、不自觉地拉脖子、眨眼和说不出话来。 由于持续的肌肉收缩，它还会引起疼痛和不适。 然而，肌张力障碍没有特定的原因，并且已知是由于与基底神经节相关的问题导致人类肌肉收缩而发生的。

肌张力障碍可以通过肉毒桿菌毒素 (Botox) 注射、几种药物和手术治疗。 这些方法可以单独或组合用于治疗肌张力障碍。 用于治疗肌张力障碍的药物包括肌肉鬆弛剂、抗胆碱能药、抗惊厥药和多巴胺能药物。 对这些药物的反应因人而异，并且可能因症状的严重程度而异。

推动肌张力障碍治疗市场增长的主要因素包括发达国家和新兴市场肌张力障碍发病率的增加，以及帕金森病和亨廷顿舞蹈病等疾病的患病率增加。. 例如，根据帕金森基金会的数据，美国每年有近 9 万人被诊断出患有帕金森病，全世界有超过 1000 万人患有帕金森病。 帕金森病和肌张力障碍彼此密切相关，帕金森病患病率的增加增加了肌张力障碍的发病率。 这将进一步增加对肌张力障碍疗法的需求，推动肌张力障碍疗法市场的增长。

内容

第一章介绍

第 2 章执行摘要

第 3 章市场概述

  • 市场定义和范围
  • 主要发现
    • 主要影响因素
    • 主要投资机会
  • 波特的五力分析
    • 供应商的议价能力
    • 买家的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 中等强度的竞争
  • 市场动态
    • 司机
      • 增加製药领域的研发活动
      • 肌张力障碍的发生率增加
      • 神经系统疾病的患病率增加
    • 约束因素
      • 发展中国家缺乏对肌张力障碍的认识
    • 机会
      • 新兴市场的增长机会
  • 分析 COVID-19 对市场的影响

第 4 章。肌张力障碍药物市场：按药物类型分类

  • 概览
    • 市场规模和预测
  • 多巴胺激动剂
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • GABA 激动剂
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 抗惊厥药
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 其他
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 5 章肌张力障碍药物市场：按给药途径

  • 概览
    • 市场规模和预测
  • 口语
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 可注射
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 6 章肌张力障碍药物市场：按分销渠道

  • 概览
    • 市场规模和预测
  • 医院药房
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 在线提供商
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 药店和零售药店
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 7 章肌张力障碍药物市场：按地区

  • 概览
    • 市场规模和预测：按地区
  • 北美
    • 主要趋势和机会
    • 市场规模和预测：按药物分类
    • 市场规模和按给药途径预测
    • 按分销渠道划分的市场规模和预测
    • 市场规模和预测：按国家/地区分类
      • 美国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按药物分类
      • 市场规模和按给药途径预测
      • 按分销渠道划分的市场规模和预测
      • 加拿大
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按药物分类
      • 市场规模和按给药途径预测
      • 按分销渠道划分的市场规模和预测
      • 墨西哥
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按药物分类
      • 市场规模和按给药途径预测
      • 按分销渠道划分的市场规模和预测
  • 欧洲
    • 主要趋势和机会
    • 市场规模和预测：按药物分类
    • 市场规模和按给药途径预测
    • 按分销渠道划分的市场规模和预测
    • 市场规模和预测：按国家/地区分类
      • 德国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按药物分类
      • 市场规模和按给药途径预测
      • 按分销渠道划分的市场规模和预测
      • 法国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按药物分类
      • 市场规模和按给药途径预测
      • 按分销渠道划分的市场规模和预测
      • 英国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按药物分类
      • 市场规模和按给药途径预测
      • 按分销渠道划分的市场规模和预测
      • 意大利
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按药物分类
      • 市场规模和按给药途径预测
      • 按分销渠道划分的市场规模和预测
      • 西班牙
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按药物分类
      • 市场规模和按给药途径预测
      • 按分销渠道划分的市场规模和预测
      • 其他欧洲
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按药物分类
      • 市场规模和按给药途径预测
      • 按分销渠道划分的市场规模和预测
  • 亚太地区
    • 主要趋势和机会
    • 市场规模和预测：按药物分类
    • 市场规模和按给药途径预测
    • 按分销渠道划分的市场规模和预测
    • 市场规模和预测：按国家/地区分类
      • 日本
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按药物分类
      • 市场规模和按给药途径预测
      • 按分销渠道划分的市场规模和预测
      • 中国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按药物分类
      • 市场规模和按给药途径预测
      • 按分销渠道划分的市场规模和预测
      • 澳大利亚
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按药物分类
      • 市场规模和按给药途径预测
      • 按分销渠道划分的市场规模和预测
      • 印度
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按药物分类
      • 市场规模和按给药途径预测
      • 按分销渠道划分的市场规模和预测
      • 韩国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按药物分类
      • 市场规模和按给药途径预测
      • 按分销渠道划分的市场规模和预测
      • 其他亚太地区
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按药物分类
      • 市场规模和按给药途径预测
      • 按分销渠道划分的市场规模和预测
  • 拉丁美洲/中东/非洲
    • 主要趋势和机会
    • 市场规模和预测：按药物分类
    • 市场规模和按给药途径预测
    • 按分销渠道划分的市场规模和预测
    • 市场规模和预测：按国家/地区分类
      • 巴西
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按药物分类
      • 市场规模和按给药途径预测
      • 按分销渠道划分的市场规模和预测
      • 沙特阿拉伯
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按药物分类
      • 市场规模和按给药途径预测
      • 按分销渠道划分的市场规模和预测
      • 南非
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按药物分类
      • 市场规模和按给药途径预测
      • 按分销渠道划分的市场规模和预测
      • 拉丁美洲其他地区/中东/非洲
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按药物分类
      • 市场规模和按给药途径预测
      • 按分销渠道划分的市场规模和预测

第八章竞争格局

  • 介绍
  • 关键成功策略
  • 10 家主要公司的产品映射
  • 比赛仪表板
  • 竞争热图
  • 定位顶级公司，2021 年

第九章公司简介

  • Abbvie Inc
  • F. Hoffmann-La Roche Ltd.
  • Hameln Pharma Gmbh
  • Ipsen Pharma
  • Merz Pharmaceuticals, LLC
  • Novartis AG
  • Pfizer Inc.
  • Wellona Pharma
  • Teva Pharmaceutical Industries Limited
  • Amneal Pharmaceuticals LLC
Product Code: A13938

The global dystonia drugs market was valued at $806.67 million in 2021, and is projected to reach $1,378.67 million by 2031, registering a CAGR of 5.5% from 2022 to 2031. Dystonia may be defined as a movement disorder which is characterized by involuntary contraction of the muscles which causes repetitive or twisting movements. This condition may affect a single (focal dystonia) or two parts (segmental dystonia) of the body or can affect the whole body of the patient which is termed as (general dystonia). These muscle contractions can be mild or severe in nature and can affect the movement of the person due to abnormal posture. Moreover, women are more prone to the condition than the men. Symptoms of dystonia include the cramping of the foot, involuntary pulling of the neck, uncontrollable blinking, speech difficulties and others. People also suffer from pain and discomfort as a result of constant muscle contractions. However, dystonia does not have a specific cause but is known to occur as a result of problems related to basal ganglia which leads to muscle contractions in the person.  

Major approaches for treating dystonia include botulinum toxin (botox) injections, several drug types of medication and surgery. These approaches can be used individually or in combination for treating dystonia. In addition, the drugs used for the treatment of dystonia includes muscle relaxants, anticholinergic drugs, anticonvulsants, dopaminergic agents and others. The response to these medications depends on different individuals and may also differ according to the severity of the condition.  

The major factor driving the growth of dystonia drugs market includes the increase in incidences of dystonia in developed and developing regions, along with increase in prevalence of conditions such as Parkinson's disease, Huntington's disease and others. For instance, according to The Parkinson's Foundation, nearly 90,000 people in the U.S. are diagnosed with Parkinson's disease each year and more than 10 million people worldwide are living with Parkinson's disease. As Parkison's disease and dystonia are closely related to each other, increase in prevalence of Parkinsons diseases increases the incidence of dystonia. This further increases the demand for dystonia treatment drugs and thus, propels the growth of dystonia drugs market.  

In addition, major key players are offering a wide range of dystonia drug products with significant product differentiation. Manufacturers are focusing on developing novel formulations which are highly potent and effective and are easily accessible to the patients. Thus, increase in such product offering by the key market players is anticipated to increase the prescription of various dystonia medications by healthcare providers and patients and thereby augment the growth of the market.  

Furthermore, the increase in funding and investment by the key market players in the developing regions is boosting the market growth. Regions such as Asia-Pacific have been the point of attraction for the investors owing to the presence of essential resources in this region. Moreover, Asia-Pacific is emerging as a pharmaceutical hub for supply of medications and devices around the globe. This also propels the growth dystonia drugs market. 

Although various key factors are driving the growth of the market, there are few factors such as lack of awareness about the condition and its treatment options in underdeveloped countries is providing hindrance to the growth of the market. Dystonia is often left undiagnosed as people have less knowledge regarding the condition. Also, people in developing countries are unaware about the advanced treatment options available for dystonia. Also, availability of new alternate treatment options such as surgeries and other physical therapies, further acts as a restraint to the growth of the market.  

The global dystonia drugs market is segmented on the basis of drug type, distribution channel and region. By drug type, the market is categorized into dopaminergic agents, GABAergic agents, anticonvulsants, and others. On the basis of route of administration, the market is segmented into oral and injection. Based on distribution channel, the market is categorized into hospital pharmacies, online providers and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). 

Major Key players that operate in the global Dystonia Drugs Market are: AbbVie Inc., Amneal Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd, Hameln Pharma GmbH, Ipsen Pharma, Merz Pharmaceuticals, LLC, Novartis AG, Pfizer Inc., Teva Pharmaceuticals and Wellona Pharma.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the dystonia drugs market analysis from 2021 to 2031 to identify the prevailing dystonia drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the dystonia drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global dystonia drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type

  • Anticonvulsants drugs
  • Others
  • Dopaminergic agents
  • GABAergic agents

By Route of Administration

  • Oral
  • Injectable

By Distribution Channel

  • Hospital Pharmacies
  • Online Providers
  • Drug Stores and Retail Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players

  • Hameln Pharma Gmbh
  • Ipsen Pharma
  • Novartis AG
  • Pfizer Inc.
  • Wellona Pharma
  • Teva Pharmaceutical Industries Limited
  • Amneal Pharmaceuticals LLC
  • F. Hoffmann-La Roche Ltd.
  • Merz Pharmaceuticals, LLC
  • Abbvie Inc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate bargaining power of buyers
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate threat of new entrants
    • 3.3.5. Moderate intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in R&D activities in pharmaceutical field
      • 3.4.1.2. Increase in incidences of dystonia
      • 3.4.1.3. Increase in prevalence of neurological disorders
    • 3.4.2. Restraints
      • 3.4.2.1. Lack of awareness about dystonia in underdeveloped nations
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunity in emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: DYSTONIA DRUGS MARKET, BY DRUG TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Dopaminergic agents
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. GABAergic agents
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Anticonvulsants drugs
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Oral
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Injectable
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Online Providers
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Drug Stores and Retail Pharmacies
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: DYSTONIA DRUGS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Drug Type
    • 7.2.3. Market size and forecast, by Route of Administration
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Drug Type
      • 7.2.5.1.3. Market size and forecast, by Route of Administration
      • 7.2.5.1.4. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Drug Type
      • 7.2.5.2.3. Market size and forecast, by Route of Administration
      • 7.2.5.2.4. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Drug Type
      • 7.2.5.3.3. Market size and forecast, by Route of Administration
      • 7.2.5.3.4. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Drug Type
    • 7.3.3. Market size and forecast, by Route of Administration
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Drug Type
      • 7.3.5.1.3. Market size and forecast, by Route of Administration
      • 7.3.5.1.4. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Drug Type
      • 7.3.5.2.3. Market size and forecast, by Route of Administration
      • 7.3.5.2.4. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Drug Type
      • 7.3.5.3.3. Market size and forecast, by Route of Administration
      • 7.3.5.3.4. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Drug Type
      • 7.3.5.4.3. Market size and forecast, by Route of Administration
      • 7.3.5.4.4. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Drug Type
      • 7.3.5.5.3. Market size and forecast, by Route of Administration
      • 7.3.5.5.4. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Drug Type
      • 7.3.5.6.3. Market size and forecast, by Route of Administration
      • 7.3.5.6.4. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Drug Type
    • 7.4.3. Market size and forecast, by Route of Administration
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Drug Type
      • 7.4.5.1.3. Market size and forecast, by Route of Administration
      • 7.4.5.1.4. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Drug Type
      • 7.4.5.2.3. Market size and forecast, by Route of Administration
      • 7.4.5.2.4. Market size and forecast, by Distribution Channel
      • 7.4.5.3. Australia
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Drug Type
      • 7.4.5.3.3. Market size and forecast, by Route of Administration
      • 7.4.5.3.4. Market size and forecast, by Distribution Channel
      • 7.4.5.4. India
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Drug Type
      • 7.4.5.4.3. Market size and forecast, by Route of Administration
      • 7.4.5.4.4. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Drug Type
      • 7.4.5.5.3. Market size and forecast, by Route of Administration
      • 7.4.5.5.4. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Drug Type
      • 7.4.5.6.3. Market size and forecast, by Route of Administration
      • 7.4.5.6.4. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Drug Type
    • 7.5.3. Market size and forecast, by Route of Administration
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Drug Type
      • 7.5.5.1.3. Market size and forecast, by Route of Administration
      • 7.5.5.1.4. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Drug Type
      • 7.5.5.2.3. Market size and forecast, by Route of Administration
      • 7.5.5.2.4. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Drug Type
      • 7.5.5.3.3. Market size and forecast, by Route of Administration
      • 7.5.5.3.4. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Drug Type
      • 7.5.5.4.3. Market size and forecast, by Route of Administration
      • 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Abbvie Inc
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. F. Hoffmann-La Roche Ltd.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Hameln Pharma Gmbh
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
  • 9.4. Ipsen Pharma
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Merz Pharmaceuticals, LLC
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Key strategic moves and developments
  • 9.6. Novartis AG
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Pfizer Inc.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Wellona Pharma
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
  • 9.9. Teva Pharmaceutical Industries Limited
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Amneal Pharmaceuticals LLC
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 02. DYSTONIA DRUGS MARKET FOR DOPAMINERGIC AGENTS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 03. DYSTONIA DRUGS MARKET FOR GABAERGIC AGENTS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 04. DYSTONIA DRUGS MARKET FOR ANTICONVULSANTS DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 05. DYSTONIA DRUGS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 06. GLOBAL DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 07. DYSTONIA DRUGS MARKET FOR ORAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 08. DYSTONIA DRUGS MARKET FOR INJECTABLE, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 09. GLOBAL DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. DYSTONIA DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. DYSTONIA DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. DYSTONIA DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. DYSTONIA DRUGS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. NORTH AMERICA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. NORTH AMERICA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. NORTH AMERICA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. NORTH AMERICA DYSTONIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. U.S. DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. U.S. DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. U.S. DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. CANADA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. CANADA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. CANADA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. MEXICO DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. MEXICO DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. MEXICO DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. EUROPE DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. EUROPE DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. EUROPE DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. EUROPE DYSTONIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. GERMANY DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. GERMANY DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. GERMANY DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. FRANCE DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. FRANCE DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. FRANCE DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. UK DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. UK DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. UK DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. ITALY DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. ITALY DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. ITALY DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. SPAIN DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. SPAIN DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. SPAIN DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. REST OF EUROPE DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. REST OF EUROPE DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. REST OF EUROPE DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. ASIA-PACIFIC DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. ASIA-PACIFIC DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. ASIA-PACIFIC DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. ASIA-PACIFIC DYSTONIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. JAPAN DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. JAPAN DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. JAPAN DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. CHINA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. CHINA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. CHINA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. AUSTRALIA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. AUSTRALIA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. AUSTRALIA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. INDIA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. INDIA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. INDIA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. SOUTH KOREA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. SOUTH KOREA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. SOUTH KOREA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. LAMEA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. LAMEA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. LAMEA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. LAMEA DYSTONIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. BRAZIL DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. BRAZIL DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. BRAZIL DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. SAUDI ARABIA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. SAUDI ARABIA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. SAUDI ARABIA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. SOUTH AFRICA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. SOUTH AFRICA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. SOUTH AFRICA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. REST OF LAMEA DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. REST OF LAMEA DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. REST OF LAMEA DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. ABBVIE INC: KEY EXECUTIVES
  • TABLE 88. ABBVIE INC: COMPANY SNAPSHOT
  • TABLE 89. ABBVIE INC: PRODUCT SEGMENTS
  • TABLE 90. ABBVIE INC: PRODUCT PORTFOLIO
  • TABLE 91. ABBVIE INC: KEY STRATERGIES
  • TABLE 92. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 93. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 94. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 95. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 96. HAMELN PHARMA GMBH: KEY EXECUTIVES
  • TABLE 97. HAMELN PHARMA GMBH: COMPANY SNAPSHOT
  • TABLE 98. HAMELN PHARMA GMBH: PRODUCT SEGMENTS
  • TABLE 99. HAMELN PHARMA GMBH: PRODUCT PORTFOLIO
  • TABLE 100. IPSEN PHARMA: KEY EXECUTIVES
  • TABLE 101. IPSEN PHARMA: COMPANY SNAPSHOT
  • TABLE 102. IPSEN PHARMA: PRODUCT SEGMENTS
  • TABLE 103. IPSEN PHARMA: PRODUCT PORTFOLIO
  • TABLE 104. MERZ PHARMACEUTICALS, LLC: KEY EXECUTIVES
  • TABLE 105. MERZ PHARMACEUTICALS, LLC: COMPANY SNAPSHOT
  • TABLE 106. MERZ PHARMACEUTICALS, LLC: PRODUCT SEGMENTS
  • TABLE 107. MERZ PHARMACEUTICALS, LLC: PRODUCT PORTFOLIO
  • TABLE 108. MERZ PHARMACEUTICALS, LLC: KEY STRATERGIES
  • TABLE 109. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 110. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 111. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 112. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 113. PFIZER INC.: KEY EXECUTIVES
  • TABLE 114. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 115. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 116. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 117. WELLONA PHARMA: KEY EXECUTIVES
  • TABLE 118. WELLONA PHARMA: COMPANY SNAPSHOT
  • TABLE 119. WELLONA PHARMA: PRODUCT SEGMENTS
  • TABLE 120. WELLONA PHARMA: PRODUCT PORTFOLIO
  • TABLE 121. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 122. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 123. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 124. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 125. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
  • TABLE 126. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
  • TABLE 127. AMNEAL PHARMACEUTICALS LLC: PRODUCT SEGMENTS
  • TABLE 128. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
  • TABLE 129. AMNEAL PHARMACEUTICALS LLC: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. DYSTONIA DRUGS MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF DYSTONIA DRUGS MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN DYSTONIA DRUGS MARKET (2022-2031)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALDYSTONIA DRUGS MARKET
  • FIGURE 10. DYSTONIA DRUGS MARKET, BY DRUG TYPE, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR DOPAMINERGIC AGENTS, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR GABAERGIC AGENTS, BY COUNTRY 2021-2031(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR ANTICONVULSANTS DRUGS, BY COUNTRY 2021-2031(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 15. DYSTONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR ORAL, BY COUNTRY 2021-2031(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR INJECTABLE, BY COUNTRY 2021-2031(%)
  • FIGURE 18. DYSTONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021-2031(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF DYSTONIA DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 22. DYSTONIA DRUGS MARKET BY REGION, 2021
  • FIGURE 23. U.S. DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 24. CANADA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. MEXICO DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. GERMANY DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. FRANCE DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. UK DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. ITALY DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. SPAIN DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. REST OF EUROPE DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. JAPAN DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. CHINA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. AUSTRALIA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. INDIA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. SOUTH KOREA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. REST OF ASIA-PACIFIC DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. BRAZIL DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. SAUDI ARABIA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. SOUTH AFRICA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. REST OF LAMEA DYSTONIA DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46. COMPETITIVE DASHBOARD
  • FIGURE 47. COMPETITIVE HEATMAP: DYSTONIA DRUGS MARKET
  • FIGURE 48. TOP PLAYER POSITIONING, 2021
  • FIGURE 49. ABBVIE INC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 50. ABBVIE INC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 51. ABBVIE INC: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 52. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 53. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 54. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 55. IPSEN PHARMA: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 56. IPSEN PHARMA: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 57. IPSEN PHARMA: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 58. NOVARTIS AG: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 59. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 60. NOVARTIS AG: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 61. PFIZER INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 62. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 63. PFIZER INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 64. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 65. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 66. AMNEAL PHARMACEUTICALS LLC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 67. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE BY SEGMENT, 2021 (%)